GLP-1 Peptide Exendin-4 Protects Against Diabetic Eye Disease by Regulating a Key Growth Factor
Exendin-4, a GLP-1 receptor agonist peptide originally derived from Gila monster venom, suppressed diabetic retinopathy in both cell and rat models by downregulating the growth factor TGFB2.
Quick Facts
What This Study Found
Exendin-4 inhibited the progression of diabetic retinopathy in both a high-glucose-induced human retinal endothelial cell (HREC) model and a streptozotocin (STZ)-induced rat model of diabetic retinopathy.
The peptide's protective effects included reduced cell death, inhibited abnormal blood vessel tube formation, and suppressed inflammatory markers. Mechanistically, Exendin-4 downregulated TGFB2 (transforming growth factor beta-2) expression. When TGFB2 was overexpressed in cells, Exendin-4's protective effects were reversed, establishing TGFB2 as the mediating pathway.
Key Numbers
How They Did This
The study used two complementary models: (1) human retinal endothelial cells (HRECs) cultured in high-glucose conditions (in vitro), and (2) STZ-induced diabetic rats (in vivo). Techniques included qRT-PCR for gene expression, CCK-8 for cell viability, TUNEL for cell death detection, western blotting for protein levels, tube formation assays for angiogenesis, and ELISA for cytokine measurements. TGFB2 overexpression experiments confirmed the mechanism.
Why This Research Matters
GLP-1 agonists like exenatide (based on Exendin-4) and semaglutide are already widely prescribed for diabetes and obesity. If they also protect against diabetic retinopathy — one of diabetes' most feared complications — patients taking these drugs may get an important bonus benefit. This could influence prescribing decisions toward GLP-1 agonists for diabetic patients at risk of eye disease.
The Bigger Picture
This study adds to growing evidence that GLP-1 agonists have benefits far beyond blood sugar control — including neuroprotection, cardiovascular protection, and now retinal protection. As these drugs become some of the most prescribed medications worldwide, understanding their tissue-protective effects could expand their therapeutic indications and inform clinical decision-making for diabetic complications.
What This Study Doesn't Tell Us
The study used STZ-induced diabetes in rats, which models type 1 rather than type 2 diabetes — the form most commonly treated with GLP-1 agonists. The in vitro model used high glucose alone, which doesn't capture the full complexity of diabetic retinopathy. Specific dosing details and long-term effects were not described in the abstract. No human clinical data were presented.
Questions This Raises
- ?Do patients already taking GLP-1 agonists like exenatide or semaglutide show lower rates of diabetic retinopathy in real-world clinical data?
- ?Could Exendin-4 or similar peptides be administered directly to the eye (intravitreal injection) for more targeted retinal protection?
- ?Does the TGFB2-mediated mechanism apply to other diabetic microvascular complications like nephropathy or neuropathy?
Trust & Context
- Key Stat:
- TGFB2 identified as key target Exendin-4's retinal protection was abolished when TGFB2 was overexpressed, pinpointing this growth factor as the critical mediator of the peptide's protective effect in diabetic eye disease
- Evidence Grade:
- This is a preclinical study using cell culture and a rat model of diabetes. While it provides clear mechanistic evidence, no human clinical data exist for Exendin-4's retinal effects specifically, placing this at an early translational stage.
- Study Age:
- Published in 2025, this is a recent contribution to the growing body of evidence on GLP-1 agonists' protective effects beyond metabolic control.
- Original Title:
- Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro.
- Published In:
- Archives of physiology and biochemistry, 131(1), 1-10 (2025)
- Authors:
- Liu, Jufen, Wang, Huijing, Huang, Cuiting
- Database ID:
- RPEP-12216
Evidence Hierarchy
Frequently Asked Questions
What is Exendin-4 and how is it related to diabetes drugs like Byetta?
Exendin-4 is a peptide originally discovered in Gila monster venom that mimics the human gut hormone GLP-1. It became the basis for exenatide (brand name Byetta), one of the first GLP-1 agonist drugs approved for type 2 diabetes. This study explores whether it could also protect against diabetic eye damage.
Could GLP-1 drugs prevent blindness in people with diabetes?
This preclinical study suggests it's possible — Exendin-4 reduced retinal damage in diabetic rats by suppressing a harmful growth factor. While clinical trials in humans haven't been done yet for this specific indication, it adds to evidence that GLP-1 drugs may protect multiple organs beyond their blood sugar-lowering effects.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12216APA
Liu, Jufen; Wang, Huijing; Huang, Cuiting. (2025). Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro.. Archives of physiology and biochemistry, 131(1), 1-10. https://doi.org/10.1080/13813455.2023.2274279
MLA
Liu, Jufen, et al. "Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro.." Archives of physiology and biochemistry, 2025. https://doi.org/10.1080/13813455.2023.2274279
RethinkPeptides
RethinkPeptides Research Database. "Exendin-4, a GLP-1 receptor agonist, suppresses diabetic ret..." RPEP-12216. Retrieved from https://rethinkpeptides.com/research/liu-2025-exendin4-a-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.